> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# TenNor buys a seven-month reprieve from Grand Life Science as CDE review pushes H. pylori drug past year-end
- URL: https://chinapharmadesk.com/tennor-rifasutenizol-grand-life-deadline-extension/
- Published: 2026-11-13T16:22:17.000Z
- Updated: 2026-11-15T02:54:08.000Z
- Description: TenNor Therapeutics (06872.HK) and Grand Life Science extended the China approval termination deadline on H. pylori drug rifasutenizol (TNP-2198) from Dec 31, 2026 to July 31, 2027 after a CDE supplement.
- Author: Lin Yi
- Tags: Desk brief, Deals & BD, Regulation, Pipeline

With 49 days left before a contractual walk-away trigger, newly listed Chapter 18A biotech TenNor Therapeutics (Suzhou) Limited (`HKEX: 06872`) signed a supplemental agreement on November 12, 2026 with Grand Life Sciences Group extending the approval deadline on its lead antibacterial candidate rifasutenizol (`TNP-2198`) from December 31, 2026 to July 31, 2027\. According to TenNor’s [November 13 HKEX filing](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1113/2026111300901.pdf?ref=chinapharmadesk.com) (`06872.HK`), Grand Life Science previously held the right to unilaterally terminate their exclusive Greater China (excluding Taiwan) commercialization pact by written notice if rifasutenizol missed year-end Chinese marketing approval. TenNor filed its China NDA in August 2025, received a supplementary information notice from the [Center for Drug Evaluation (CDE)](https://chinapharmadesk.com/china-pharma-glossary/) in June 2026, and has now completed submitting its response package—leaving final NMPA clearance as the sole gate before launch.

## How a June CDE supplement reset a RMB 775m commercialization clock

TenNor went public on the Hong Kong Stock Exchange in May 2026 (prospectus dated May 14, 2026) with rifasutenizol positioned as its near-commercial anchor. Under the original [November 2024 partnership](http://www.tennortherapeutics.com/en/NewsD.html?id=506&ref=chinapharmadesk.com) with Grand Life Sciences subsidiary Hangzhou Grand Biologic Pharmaceutical—worth up to RMB 775 million (approx. $107.6 million) across upfront, commercial, and sales milestones, and first amended in January 2026—TenNor retains marketing authorization holder (MAH) status and manufacturing responsibility while paying Grand Life Science promotion service fees across mainland China, Hong Kong, and Macau.

The November 12 amendment illustrates how domestic Chinese commercialization contracts price regulatory review risk onto biotech licensors:

| Milestone / Contract Term                | Original Schedule                    | Updated Status (Nov 13, 2026)               |
| ---------------------------------------- | ------------------------------------ | ------------------------------------------- |
| Commercialization pact signed            | November 2024 (up to RMB 775m total) | Other financial & territory terms unchanged |
| China NDA submission (TNP-2198 capsules) | Accepted August 2025                 | Under NMPA / CDE review                     |
| CDE supplementary dossier clock          | Triggered June 2026                  | All supplementary responses submitted       |
| Partner unilateral termination trigger   | December 31, 2026                    | **Extended to July 31, 2027 (+7 months)**   |

In China’s NDA workflow, a CDE supplementary information notice (*fahu* / *buchong ziliao*) pauses the active review clock while the applicant compiles additional CMC or clinical analyses, routinely pushing total review time from 12–14 months toward 18–22 months. Extending the walk-away date to July 31, 2027 aligns the contract’s survival window with a realistic post-supplement decision in the first half of 2027 without reopening milestone or fee splits—a cleaner outcome than the [litigation and repriced equity settlement recently seen at TYK Medicines (02410.HK)](https://chinapharmadesk.com/tyk-qilu-repriced-hshare-placement/) when launch timelines collided with partner expectations.

## Clinical stakes: overcoming China’s antibiotic-resistant H. pylori burden

Rifasutenizol (`TNP-2198`) is a rifamycin-nitroimidazole conjugate designed as the first new molecular entity developed specifically for *Helicobacter pylori* infection in more than three decades, pairing bacterial RNA polymerase inhibition with nitroreductase-activated free-radical DNA damage. It holds U.S. FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations.

In China—where *H. pylori* prevalence sits near 50% and standard consensus guidelines rely on four-drug bismuth regimens—widespread macrolide and nitroimidazole resistance has eroded empirical cure rates. In TenNor’s 40-center, 700-patient Chinese Phase 3 `EVEREST-HP` trial ([NCT05857163](https://clinicaltrials.gov/study/NCT05857163?ref=chinapharmadesk.com), led by Peking University Third Hospital and published in [*The Lancet Infectious Diseases*](https://doi.org/10.1016/S1473-3099%2825%2900438-4?ref=chinapharmadesk.com)), baseline culture testing across 579 isolates showed **41% resistance to clarithromycin, 68% to metronidazole, and 35% to levofloxacin**, with zero isolates resistant to rifasutenizol:

- **Eradication efficacy:** Rifasutenizol-based triple therapy (paired with rabeprazole and amoxicillin) achieved a **92.0% (`323/351`)** modified intention-to-treat eradication rate versus **87.9% (`304/346`)** for bismuth-plus-clarithromycin quadruple therapy (absolute difference `4.2%`; 95% CI `-0.3% to 8.8%`), meeting non-inferiority while dropping bismuth and clarithromycin.
- **Tolerability edge:** Treatment-emergent adverse events occurred in **37% (`131/351`)** of patients on the rifasutenizol regimen versus **53% (`184/346`)** on the bismuth-clarithromycin control, largely eliminating metallic taste perversion (`<5%` vs. `36%`).

Alongside its October 30 decision to prioritize intra-articular dosing in prosthetic joint infection for its second core drug rifaquizinone (`TNP-2092`, [November 12 R&D update](https://static.cninfo.com.cn/finalpage/2026-11-12/1225668495.PDF?ref=chinapharmadesk.com)), TenNor’s near-term commercial transition now rides on clearing NMPA’s final review and pre-approval GMP inspection before the new July 31, 2027 contractual cutoff—and whether approval arrives in time for China’s mid-2027 [National Reimbursement Drug List (NRDL)](https://chinapharmadesk.com/china-pharma-glossary/) submission window.